home · filing · 0001664710-23-000025
8-K filed April 19, 2023, 7:59 PM ET
ticker KROS
CIK 0001664710
leadership
confidence high
sentiment neutral
materiality 0.25
Keros Therapeutics appoints Alpna Seth, Ph.D., to board effective May 1, 2023
Keros Therapeutics, Inc.
Board increased to eight members; Dr. Seth appointed as Class II director with term through 2025 annual meeting.
Dr. Seth will serve on the Compensation Committee.
Initial option grant of 20,000 shares vesting quarterly over three years; annual retainer $40,000 (board) plus $6,000 (committee).
Dr. Seth previously CEO of Nura Bio, COO of Vir Biotechnology, and SVP at Biogen.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2023-05-01
Filed April 19, 2023, 7:59 PM ET
Dr. Alpna Seth as a director of the Company, effective on May 1, 2023.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Dr. Alpna Seth was appointed as director at Keros Therapeutics, Inc..
Action appointed
Role director
Exact text from the filing
Dr. Alpna Seth as a director of the Company, effective on May 1, 2023.
View on SEC.gov
Source: SEC EDGAR
accession 0001664710-23-000025
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.